Percutaneous Ablation Versus Surgical Resection for Local Recurrence Following Partial Nephrectomy for Renal Cell Cancer: A Propensity Score Analysis (REPART Study-UroCCR 71).


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 13 09 2020
revised: 20 12 2020
accepted: 09 02 2021
pubmed: 25 2 2021
medline: 15 4 2022
entrez: 24 2 2021
Statut: ppublish

Résumé

Data comparing percutaneous ablation (PCA) and surgical resection (SR) for an isolated local recurrence (LR) following partial nephrectomy (PN) for renal cell carcinoma (RCC) are lacking. To examine the outcomes between PCA and SR for an isolated LR following PN for RCC. Patients who underwent PN for RCC and developed an LR between 2013 and 2019 were included. An LR was defined as the appearance of a mass in contact with the resection bed or the development of a tumor in the same region of the homolateral kidney as the original site. PCA or SR. To achieve balance in baseline characteristics, we used inverse probability of treatment weighting (IPTW) based on propensity to receive treatment. Oncological outcomes, complications, and renal function were evaluated between groups using logistic, linear, and Cox proportional hazard regression models. A total of 81 patients with an isolated LR were included (PCA: 42; SR: 39). The median follow-up was 23 mo. After adjustment, excellent balance was achieved for the majority of propensity score variables. In IPTW analysis, PCA was associated with a lower risk of postoperative complications (odds ratio=0.22; p=0.006) and a smaller change in eGFR (beta=-16.18; p=0.001). There were no significant differences in the risk of disease recurrence (hazard ratio [HR]=0.72; p=0.61), new LR (HR=1.51; p=0.59), and distant metastasis (HR=0.19; p=0.09). Limitations include the sample size and unmeasured confounding factors. Our results suggest that PCA provides comparable oncological outcomes to repeat surgery with fewer complications and better renal function preservation for the management of an LR after PN. This report shows that percutaneous ablation can be used for treating a local recurrence of renal cell carcinoma after partial nephrectomy, without significantly compromising cancer control.

Sections du résumé

BACKGROUND BACKGROUND
Data comparing percutaneous ablation (PCA) and surgical resection (SR) for an isolated local recurrence (LR) following partial nephrectomy (PN) for renal cell carcinoma (RCC) are lacking.
OBJECTIVE OBJECTIVE
To examine the outcomes between PCA and SR for an isolated LR following PN for RCC.
DESIGN, SETTING, AND PARTICIPANTS METHODS
Patients who underwent PN for RCC and developed an LR between 2013 and 2019 were included. An LR was defined as the appearance of a mass in contact with the resection bed or the development of a tumor in the same region of the homolateral kidney as the original site.
INTERVENTION METHODS
PCA or SR.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
To achieve balance in baseline characteristics, we used inverse probability of treatment weighting (IPTW) based on propensity to receive treatment. Oncological outcomes, complications, and renal function were evaluated between groups using logistic, linear, and Cox proportional hazard regression models.
RESULTS AND LIMITATIONS CONCLUSIONS
A total of 81 patients with an isolated LR were included (PCA: 42; SR: 39). The median follow-up was 23 mo. After adjustment, excellent balance was achieved for the majority of propensity score variables. In IPTW analysis, PCA was associated with a lower risk of postoperative complications (odds ratio=0.22; p=0.006) and a smaller change in eGFR (beta=-16.18; p=0.001). There were no significant differences in the risk of disease recurrence (hazard ratio [HR]=0.72; p=0.61), new LR (HR=1.51; p=0.59), and distant metastasis (HR=0.19; p=0.09). Limitations include the sample size and unmeasured confounding factors.
CONCLUSIONS CONCLUSIONS
Our results suggest that PCA provides comparable oncological outcomes to repeat surgery with fewer complications and better renal function preservation for the management of an LR after PN.
PATIENT SUMMARY RESULTS
This report shows that percutaneous ablation can be used for treating a local recurrence of renal cell carcinoma after partial nephrectomy, without significantly compromising cancer control.

Identifiants

pubmed: 33622625
pii: S2405-4569(21)00050-X
doi: 10.1016/j.euf.2021.02.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

210-216

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Marie Brassier (M)

Department of Urology, Angers University Hospital, Angers, France. Electronic address: marie.brassier@hotmail.com.

Zine-Eddine Khene (ZE)

Department of Urology, Rennes University Hospital, Rennes, France.

Jean-Christophe Bernhard (JC)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Van Thi Dang (VT)

Department of Urology and Renal Transplantation, Toulouse University Hospital, Toulouse, France.

Idir Ouzaid (I)

Department of Urology, Bichat Hospital, APHP, Paris Diderot University, Paris, France.

François Xavier Nouhaud (FX)

Department of Urology, Rouen University Hospital, Rouen, France.

Jonathan Olivier (J)

Department of Urology, Lille University Hospital, Lille, France.

Cosmina Nedelcu (C)

Department of Radiology, Angers University Hospital, Angers, France.

Nicolas Grenier (N)

Department of Radiology, Bordeaux University Hospital, Bordeaux, France.

Luc Beuzit (L)

Department of Radiology, Rennes University Hospital, Rennes, France.

Nicolas Doumerc (N)

Department of Urology and Renal Transplantation, Toulouse University Hospital, Toulouse, France.

Karim Bensalah (K)

Department of Urology, Rennes University Hospital, Rennes, France.

Pierre Bigot (P)

Department of Urology, Angers University Hospital, Angers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH